A Phase I Study of Lintuzumab-Ac225 in Combination with CLAG-M Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Lintuzumab Ac-225 (Primary) ; Mitoxantrone (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

11 Jun 2024 According to a Actinium Pharmaceuticals media release, data form this trial were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 -11, 2024, in Toronto, Canada.
11 Jun 2024 Results presented in an Actinium Pharmaceuticals Media Release.
06 Jun 2024 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com